Copy to clipboard 
Bone Therapeutics and Medsenic entered into a binding contribution agreement to combine the operations of both companies by means of a share for share exchange.
The resulting business, Biosenic, will broaden and derisk Bone Therapeutics’ portfolio that targets a broad array of inflammatory and orthopedic indications.
Integrating both biopharmaceutical companies would significantly derisk and broaden Bone Therapeutic’s therapeutic portfolio, targeting an array of inflammatory and orthopedic indications. Both companies are currently running several mid- to advanced stage clinical trials ongoing in lupus, chronic graft-versus-host disease, tibial fractures and other indications. As a result, a number of economic, financial and operational benefits and synergies would arise from combining the clinical development programs within one organization.
The existing pipeline from both organizations would continue as planned. The Phase IIb trial of Bone Therapeutics’ ALLOB, a randomized, double-blind, placebo-controlled study in patients with high-risk tibial fractures, is still ongoing and set to report interim results in the first half of 2023. Medsenic is undergoing a study for the treatment of lupus.
“The addition of Medsenic, particularly with its dedicated best-in-class autoimmune disease platform, allows the respective teams of both companies to develop an expanded product portfolio across multiple therapeutic indications and thus limit shareholder risk, offer multiple treatments to patients, and increase the potential for growth and value creation for all shareholders,” said Jean Stéphenne, President of Bone Therapeutics. “The acquisition of Medsenic fits well with our strategic priorities and offers substantial financial growth potential and therapeutic solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Bone Therapeutics is well positioned to leverage Medsenic’s value proposition with a strong technology portfolio and business development experience.”
Source: Bone Therapeutics
Bone Therapeutics and Medsenic entered into a binding contribution agreement to combine the operations of both companies by means of a share for share exchange.
The resulting business, Biosenic, will broaden and derisk Bone Therapeutics' portfolio that targets a broad array of inflammatory and orthopedic indications.
Integrating both...
Bone Therapeutics and Medsenic entered into a binding contribution agreement to combine the operations of both companies by means of a share for share exchange.
The resulting business, Biosenic, will broaden and derisk Bone Therapeutics’ portfolio that targets a broad array of inflammatory and orthopedic indications.
Integrating both biopharmaceutical companies would significantly derisk and broaden Bone Therapeutic’s therapeutic portfolio, targeting an array of inflammatory and orthopedic indications. Both companies are currently running several mid- to advanced stage clinical trials ongoing in lupus, chronic graft-versus-host disease, tibial fractures and other indications. As a result, a number of economic, financial and operational benefits and synergies would arise from combining the clinical development programs within one organization.
The existing pipeline from both organizations would continue as planned. The Phase IIb trial of Bone Therapeutics’ ALLOB, a randomized, double-blind, placebo-controlled study in patients with high-risk tibial fractures, is still ongoing and set to report interim results in the first half of 2023. Medsenic is undergoing a study for the treatment of lupus.
“The addition of Medsenic, particularly with its dedicated best-in-class autoimmune disease platform, allows the respective teams of both companies to develop an expanded product portfolio across multiple therapeutic indications and thus limit shareholder risk, offer multiple treatments to patients, and increase the potential for growth and value creation for all shareholders,” said Jean Stéphenne, President of Bone Therapeutics. “The acquisition of Medsenic fits well with our strategic priorities and offers substantial financial growth potential and therapeutic solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Bone Therapeutics is well positioned to leverage Medsenic’s value proposition with a strong technology portfolio and business development experience.”
Source: Bone Therapeutics
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
